IJPSR (2018), Volume 9, Issue 4 **(Review Article)**

INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH

Received on 15 July, 2017; received in revised form, 01 November, 2017; accepted, 17 November, 2017; published 01 April, 2018

CARDIAC ARRYTHMIASIS AND ITS DETAILED PATHOPHYSIOLOGY - A REVIEW

A. Deevan Paul* and K. Manogna

SVU College of Pharmaceutical Sciences, SV University, Tirupati - 517502, Andhra Pradesh, India.

Keywords:

Cardiac arrhythmia, Ventricular arrhythmia, Ventricular myocardium and morbidity

Correspondence to Author:
A. Deevan Paul

SVU College of Pharmaceutical Sciences, SV University, Tirupati - 517502, Andhra Pradesh, India.

E-mail: deevan4@gmail.com

ABSTRACT: Amid the previous couple of years, the improvement of powerful, experimental innovations for treatment of cardiovascular arrhythmias has surpassed the pace at which itemized information of the basic science has aggregated. Cardiac arrhythmia is a group of conditions in which the heartbeat is irregular, either too fast, or too slow and is characterized by abnormal electrical conduction in the heart resulting in ineffective pumping heart rate and rhythm that is not physiologically justified. Cardiac arrhythmias are commonly classified as tachycardia (supraventricular or ventricular) or bradycardias. The specialist management of arrhythmias has changed significantly over the past decade. Abnormal impulse conduction results in reentrant excitation. Usually a combination of slowed conduction and unidirectional conduction block provides the conditions necessary for re-entry to occur. This article outlines current management strategies for atrial flutter and atrial fibrillation, with particular emphasis on curative strategies with catheter ablation and the recent data on rhythm compared with rate control strategies. The biology of arrhythmia is largely quantifiable, which allows for systematic analysis that could transform treatment strategies that are often still empirical into management based on molecular evidence.

INTRODUCTION: Cardiovascular inconveniences are regular after intense stroke and there have been a few examinations on irregular electrocardiograms (ECGs) and arrhythmias after ischemic and hemorrhagic strokes. Arrhythmias result in the anomaly of drive start or motivation conduction or a mix of both. It is currently trusted that there is an assortment of instruments that can cause unusual drive start or irregular conduction. The revelation of such multifaceted nature most likely has put us on the right track for taking in the components that really are in charge of particular clinical arrhythmias.

QUICK RESPONSE CODE

DOI: 10.13040/IJPSR.0975-8232.9(4).1363-76

Article can be accessed online on: www.ijpsr.com

DOI link: http://dx.doi.org/10.13040/IJPSR.0975-8232.9(4).1363-76

The heart activity potential is interceded by the especially all around arranged action of a decent variety of particle channels. Cardiovascular particle directs are protein edifices in the sarcolemma of cardiomyocytes which, by means of exceptionally managed opening and shutting (gating), lead a particular and quick stream of particles through a focal pore. Spatial heterogeneity of particle channel articulation underlies the diverse activity potential morphology of the distinctive parts of the heart which thus guarantees an organized constriction [1].

1. Cardiac Arrythmias: The rhythm of a normal resting adult heart is initiated from impulses generated from the sinoatrial (SA) node with a rate varying between 60 - 100 beats per minute (bpm). During sleep the rate may decrease to 30 - 50 bpm, with episodes of sinus pauses up to 3 seconds, sinoatrial block, junctional rhythms, first degree and second degree atrioventricular nodal block

occurring often enough (particularly in trained athletes) to be considered normal variants [2].

There are two basic kinds of arrhythmias.

- Bradycardia is when the heart rate is too slow - less than 60 beat per minute.
- Tachycardia is when the heart rate is too fast - more than 100 beats per minute.

Although certain physical signs present during arrhythmias can help the physician make a correct diagnosis, electrocardiography is the standard method used for recognizing cardiac arrhythmias.



FIG. 1: A) SCHEMATIC REPRESENTATION OF A CARDIOMYOCYTE DISPLAYING (ONLY) THOSE PROTEINS INVOLVED IN THE PATHOGENESIS OF INHERENT ARRHYTHMIA SYNDROMES. B) IN PANEL A, THE ACTION POTENTIALS ARE AN ALIGNED WITH ITS APPROXIMATE TIME OF ACTION DURING THE ECG. IN A PANEL B, ANKYRIN-B, ADAPTER PROTEIN INVOLVED IN THE LONG QR SYNDROME TYPE 4, IS NOT DEPICTED



FIG. 2: ECG STRIP SHOWING A NORMAL HEARTBEAT



FIG. 3: ECG STRIP SHOWING BRADYCARDIA



FIG. 4: ECG STRIP SHOWING TACHYCARDIA

Description of an Arrhythmia: Arrhythmias may be described from their following characteristics:

1. Rate (*e.g.* tachycardia or bradycardia)

a. Tachycardia is defined as three or more consecutive impulses from the same pacemaker at a rate exceeding 100 bpm in adults (*i.e.* > 8 years of age).

b. Bradycardia is defined as three or more consecutive impulses from the same pacemaker at a rate less than 60 bpm.

2. Rhythm (*e.g.* regular or irregular)
3. Origin of impulse (*i.e.* supraventricular, ventricular, or artificial pacemaker)
4. Impulse conduction (*i.e.* atrioventricular, ventriculo-atrial or block)
5. Ventricular rate [3].



FIG. 5: (A) PICTORIAL REPRESENTATION OF SINOATRIAL (SA) NODE AND ATRIOVENTRICULAR (AV) NODE (B) INTRINSIC RATES (SA) NODE AND (AV) NODE

2.1 Descriptions of Premature Ventricular Contractions: Premature ventricular contractions (PVCs), sometimes called ventricular extra beats (VEBs). Premature ventricular beats occurring after every normal beat are termed "ventricular bigeminy". PVCs that occur at intervals of 2 normal beats to 1 PVC are termed "PVCs in trigeminy". Three premature ventricular grouped together is termed a "run of PVCs" in general, runs lasting longer than three beats are referred to as

- ✓ Ventricular tachycardia
- ✓ Accelerated idioventricular rhythm
- ✓ Monomorphic ventricular tachycardia
- ✓ Polymorphic ventricular tachycardia
- ✓ Ventricular fibrillation [4].



Heart Rate	Rhythm	P wave	PR interval (sec.)	QRS (sec.)
Var.	Irregular	No P waves associated with premature beat	NA	Wide > .12

2.2 Side Effects Associated with Arrhythmias:

- ➢ Chest pain
- ➢ Fainting
- ➢ Swelling of the feet or legs
- ➢ Shortness of breath
- ➢ Abnormally fast heartbeat
- ➢ Abnormally slow heartbeat
- ➢ Dizziness or light-headedness
- ➢ Cough



FIG. 6: PREMATURE VENTRICULAR CONTRACTIONS (PVCs)

2.3 Signs and symptoms: Some arrhythmias have no signs or symptoms, but when present the most common signs or symptoms a person will experience are:

- Palpitations (a feeling that your heart has skipped a beat or is beating too hard)
- A slow heartbeat
- An irregular heartbeat
- Heart failure or cardiomyopathy, which weakens the heart and changes the way electrical signals move around the heart
- Heart tissue that is too thick or stiff or that hasn't formed normally
- Leaking or narrowed heart valves, which make the heart work too hard and can, lead to heart failure [5].

TABLE 1: SIGNS AND SYMPTOMS

Symptoms	Risk Factors
Fatigue	Cardiomyopathy
Dizziness	Hyperthyroidism and hypothyroidism
Light headedness	CAD
Fainting [syncope] or near – fainting Spells	Smoking or alcohol consumption or caffeine drug abuse
Rapid heartbeat or pounding	Sleep apnea
Shortness of breath	Genetics
Chest pain	Stress
In extreme cases, sudden and cardiac arrest	Diabetes

2.4 Pathophysiological of Arrhythmias: Heart arrhythmias caused by anomalous driving forces start irregular motivation conduction or the two components. Strange drive start incorporates improved ordinary automaticity, irregular automaticity and activated action coming about because of after depolarization. Though, the unusual driving forces are directed incorporates conduction piece and reentry. Albeit every one of these components is causes arrhythmias, it's unrealistic to demonstrate which instrument is in charge of an arrhythmia. Be that as it may, the conceivable system of assurance of numerous clinical arrhythmias in view of their qualities and conduct and to list rhythms most steady with known electrophysiological components [6 - 8].

2.5 Normal Automaticity: Normal automaticity involves the slow progressive depolarization of the membrane potential (spontaneous diastolic depolarization or phase four depolarization) until a threshold potential is reached, at which point an action potential is initiated. Although automaticity is an intrinsic property of all myocardial cells, the occurrence of spontaneous activity is prevented by the natural hierarchy of pacemaker function. The spontaneous discharge rate of the sinoatrial (SA) nodal complex exceeds that of all other subsidiary or latent pacemakers. As a result, the impulse initiated by the SA node depresses the activity of subsidiary pacemaker sites, before they can spontaneously depolarize to threshold. However, slowly depolarizing and previously suppressed pacemakers in the atrium, AV node, or ventricle can become active and assume pacemaker control of the cardiac rhythm if the SA node pacemaker becomes slow or unable to generate an impulse or if impulses generated by the SA node are unable to activate the surrounding atrial myocardium. The emergence of subsidiary or latent pacemakers under such circumstances is an appropriate fail-safe mechanism which assures that ventricular activation is maintained [9 - 12].

2.6 Role of Latent Pacemaker Cells in the Generation of Escape Beats: Application of increasing intensity of vagal stimulation (to elicit acetylcholine release and promote bradycardia) results in a shift of the origin of the heart beat from its normal site in the SA node to other sites in the atria or in the AV node. Further increases in stimulation intensity lead to very prolonged cardiac arrest and initiation of escape beats from the AV junction or the ventricles. Note: see the lack of p-wave in ECGs recorded during intense vagal stimulation (delay time above dotted line).

2.7 Abnormal Impulse Initiation:

a) Altered Normal Automaticity: Abnormal automaticity includes both reduced automaticity, which causes bradycardia, and increased automaticity, which causes tachycardia. Arrhythmias caused by abnormal automaticity can result from diverse mechanisms.

b) Enhanced Automaticity:

Primary Pacemakers: Cells from the sinoatrial node exhibiting normal automaticity. These cells are responsible for initiating the heart beat during normal function.

c) Latent (Subsidiary) Pacemakers: Non-sinoatrial node cells which are capable of automatic activation. Examples include cells from the atrioventricular (AV) junction, some fibers/cells at the pulmonary veins, and cells from the His-Purkinje system amongst others. Enhanced pacemaker can occur via three mechanisms: A negative shift in the threshold potential (TP), a positive shift in the maximum diastolic potential (MDP), and an increased rate of phase 4 depolarization. Atrial and ventricular myocardial cells do not display spontaneous diastolic depolarization or automaticity under normal conditions, but can develop these characteristics when depolarized, resulting in the development of repetitive impulse initiation, a phenomenon termed depolarization-induced automaticity.

- ✓ An increase in extracellular potassium, which reduces the reversal potential for I_{K1}, the outward current that largely determines the resting membrane or maximum diastolic potential;
- ✓ A reduced number of I_{K1}channels;
- ✓ A reduced ability of the I_{K1} channel to conduct potassium ions; or
- ✓ Electro tonic influence of neighboring cells in the depolarized zone [13 - 15].

2.8 Triggered Rhythms: Triggered activity results from the premature activation of cardiac tissues by after depolarization's, which are depolarizations

triggered by one or more preceding action potentials. One occurs early during the repolarization of the membrane, an early after depolarization, and the other occurs after the repolarization is complete or nearly completed, a delayed after depolarization [16]. When either type is large enough to reach threshold, the resulting action potential is called a triggered action potential. Triggered activity will cause arrhythmias when impulse initiation shifts from the sinus node to the triggered focus. For this, the rate of triggered impulses must be faster than the rate of the sinus node, an event that may be brought about when the sinus node has been slowed or inhibited, when it has been blocked, or when the triggered focus is intrinsically faster [17 - 19].



FIG. 7: A, B, C SHOWS THE EARLY AFTER DEPOLARIZATION AND D AND E SHOWS DELAYED AFTER DEPOLARIZATION

After - depolarization Phenomena



FIG. 8: AFTER DEPOLARIZATION PHENOMENA: EARLY AFTER DEPOLARIZATION (EAD) OCCURS EARLY (PHASE 2) OR LATE (PHASE 3), AND DELAYED AFTER DEPOLARIZATION (DAD) OCCURS DURING PHASE 4 OF THE ACTION POTENTIAL

EADs is typically observed in cardiac tissues exposed to injury, altered electrolytes, hypoxia, acidosis, catecholamines, and pharmacologic agents, including anti-arrhythmic drugs. Ventricular hypertrophy and heart failure also predispose to the development of EADs. EAD characteristics vary as a function of animal species, tissue or cell type, and the method by which the EAD is elicited. Early after depolarizations (EADs) can develop before full repolarization, corresponding to phase 2 or phase 3 of the cardiac action potential in humans [20]. They are usually but not exclusively associated with prolonged action potential durations (APDs), which occur when the inward current is greater in amplitude than the outward current. Whatever be the underlying mechanism, if the change in membrane potential brought about by the EAD is sufficiently large, it will activate I_{Na}, resulting in triggered activity. EADs and their resulting triggered activity is thought underlie the arrhythmogenesis observed in heart failure and long QT syndromes [21 - 23].

2.9 Delayed After Depolarizations: DADs and DAD-induced triggered activity are observed under conditions that augment intracellular calcium, [Ca^{2+}], such as after exposure to toxic levels of cardiac glycosides (digitalis) or catecholamine. This activity is also manifest in hypertrophied and failing hearts as well as in Purkinje fibers surviving myocardial infarction. In contrast to EADs, DADs are always induced at relatively rapid rates. Delayed after depolarizations (DADs) were first described as oscillatory after potentials. They can develop after full repolarization, corresponding to phase 4 of the cardiac action potential in humans. It is worth noting that DADs and late EADs are somewhat similar. Both occur under conditions of intracellular calcium over load and involve spontaneous release of calcium from the sarcoplasmic reticulum. The difference appears to be the timing of this release, which occurs during their polarizing phase of the action potential in the case of late EADs, and at the resting membrane potential for DADs. Indeed, for atrial fibrillation, both EADs and DADs have been implicated as the mechanisms of arrhythmogenesis [24 - 25].

2.10 Re-entry: Re-entry occurs when an action potential fails to extinguish itself and reactivates a region that has recovered from refractoriness. It can be divided into two types:

- Re-entry that occurs in the presence of an obstacle, around which an action potential can travel (circus-type)



FIG. 9: CIRCUS - TYPE RE-ENTRY

- Re-entry that occurs without an obstacle (reflection or phase 2).



FIG. 10: RE - ENTRY OCCURS WITH AN OBSTACLE

Recently, a different type of reflection, called the expansion- type, has been demonstrated. Ante grade propagation of an impulse occurs from an arrow isthmus region to an expanded distal region. The activation wave front has an outward curvature (convex) and stimulates a higher number of cells in the expanded region, where the source-sink mismatch is greatest. This causes the direction of electro tonic currents to be reversed, intern prolonging the action potential. This in turn initiates retro grade propagation long the same path [26].

3. Cardiac Ablation: Cardiac ablation is a strategy that can rectify arrhythmias. This is a method to treat atrial fibrillation (AF), a kind of sporadic pulse. It can help keep your pulse in an ordinary mood. Removal, for the most part, utilizes long, adaptable tubes (catheters) embedded through a vein in your crotch and strung to your heart to adjust auxiliary issues in your heart that reason an arrhythmia. It works by decimating tissue in the heart that triggers an unusual heartbeat. Now and again, removal keeps irregular electrical signs from going through the heart and, along these lines, stops the arrhythmia. Cardiovascular removal is in some cases done through open-heart surgery, however, it's frequently done utilizing catheters, making the technique less obtrusive and shortening recuperation times [27 - 29].

3.1 About Catheter Ablation: Catheter removal is likewise used to help control other heartbeat issues, for example, atrial shudder and atrial fibrillation. Catheter removal devastates the anomalous tissue without harming whatever is left of the heart. Extraordinary cells in the heart make electrical signs that go along pathways to the assemblies of your heart. These signs make the hearts upper and lower chambers beat in the correct arrangement. Anomalous cells might be made by sorted out electrical signs that reason sporadic or fast heartbeats called arrhythmias. At the point when this happens, the heart may not pump blood successfully and you may feel blackout, shy of breath and frail. Prescriptions to treat fast and sporadic heartbeats work exceptionally well for the vast majority. Be that as it may, they don't work for everybody, and they may cause symptoms in a few people. In these cases, specialists may recommend catheter removal. The system is utilized regularly to treat a condition called supraventricular tachycardia, which happens due to irregular conduction strands in the heart [28].





FIG. 11: REPRESENTATION OF CATHETER ABLATION IN LUMEN OF PULMONARY VEIN

3.2 Before AF Ablation:

- **An EKG (Electrocardiogram):** This simple, painless test records the heart's electrical activity. The test shows how fast the heart is beating and its rhythm. An EKG also records the strength and timing of electrical signals as they pass through your heart.
- **Echocardiography:** This is a painless test that uses sound waves to create of the heart & also show how well the heart's chambers and valves are working. Stress testing - Some heart problems are easier to diagnose when the heart is working hard and beating fast [29].

3.3 Expect After AF Ablation:

- Chest pain is common
- Arrhythmia
- Resting heart rate changes
- Digestive problems



4. Ablation for Supraventricular Arrhythmias: Although an established therapy for many years, improvements in electrophysiological techniques have led to catheter ablation becoming first line therapy for most patients with AV nodal re-entrant tachycardia (AVNRT) or WPW and for many patients with atrial flutter.

4.1 Atria Ventricular Nodal Re-entrant Tachycardia (AVNRT): AVNRT is caused by re-entry within the AV node, using ‘‘fast’’ and ‘‘slow’’ pathways. Ablation of the slow pathway to cure AVNRT has become a comparatively straightforward and routine procedure. The most significant complication associated with slow pathway ablation is damage to the fast pathway and hence AV blocks requiring pacing. In one large series of more than 8000 patients, long term cure was achieved in 99% of patients with high grade AV block necessitating pacing occurring in only 0.4%. 1. Catheter ablation has become the treatment of choice in patients with symptomatic AVNRT. Indeed, many patients and their physicians choose ablation asfirst line therapy to avoid the need for anti-arrhythmic drug therapy [30-34].

4.2 Wolff - Parkinson - White Syndrome: Arrhythmias in the WPW disorder are owing to the nearness of an extra atrioventricular association, named an "embellishment pathway". This usually gives atrioventricular re-participant tachycardia (AVRT), which is frequently very much endured. Be that as it may, patients with WPW are in danger should they create atrial fibrillation as the embellishment pathway can lead more quickly than the AV hub.

Exceptionally fast ventricular rates and ventricular fibrillation may follow. RF removal of embellishment pathways has turned out to be the first-line treatment for patients with symptomatic WPW as hostile to arrhythmic medications are regularly inadequate and ineffectively endured. In an investigation of more than 6000 patients from a few focuses, long haul achievement rates were 98%. Genuine inconveniences were seen in 0.6% with just a single casualty. The one-time danger of catheter removal is by all accounts lower than the total lifetime chance related with symptomatic WPW [35].



FIG. 12: REPRESENTATION OF NORMAL ELECTRICAL PATHWAYS AND ACCESSORY PATHWAY (BRIDGE)

4.3 Atrial Flutter: Atrial flutter is caused by a solitary flood of electrical initiation that takes a reliable way around the atria. Around 90% of atrial ripple includes a counter-clockwise revolution in the correct chamber. The atrial rate is regularly around 300/min with a subsequent ventricular rate of 150/min. The circuit engaged with commonplace vacillate has been very much characterized and includes a thin extension of tissue (regularly 1 - 2 cm) between the tricuspid valve and the second rate vena cava (IVC). This zone is known as the Cavo tricuspid isthmus (CTI). Drawing a line of removal over this territory adequately hinders the circuit for commonplace vacillate. An imminent, randomized trial of therapeutic treatment contrasted and catheter removal as the main line treatment in atrial ripple has demonstrated fundamentally better results for patients treated by removal. Patients treated by removal had decreased atrial ripple, better prosperity, and furthermore a diminishment in the beginning of atrial fibrillation.

The high achievement rate of removal (with a low frequency of inconveniences) recommends that expanding use ought to be made of removal for this arrhythmia. Vacillate removal ought to be considered as first-line treatment for three gatherings of patients: those with troublesome side effects, those in whom ventricular rate control with drugs is problematic, and in those with left ventricular brokenness because of tireless tachycardia. The central shortcoming of CTI removal for atrial shudder is the consequent beginning of AF. Albeit atrial vacillate and AF are diverse arrhythmias they are firmly associated. After removal the counter arrhythmic treatment must be kept on stifling further AF, yet arrhythmia control is by and large great with this system. In some other patient's atrial vacillate is an imperative forerunner to AF and ripple removal would then be able to likewise be a successful hostile to arrhythmic technique [36 - 39].



FIG. 13: REPRESENTATION OF NORMAL SINUS RHYTHM AND ATRIAL FLUTTER

4.4 Atrial Fibrillation: There are two important areas that have changed in the management of AF over the past five years. The first is the publication of several studies addressing the issue of rate compared with rhythm control. The second is the use of ablation as a curative therapy for patients with AF.



FIG. 14: MANAGEMENT OF NORMAL HEART AND HEART WITH ATRIAL FIBRILLATION

5. Ventricular Tachycardia and Ventricular Fibrillation: Ventricular fibrillation (VF) and ventricular tachycardia (VT) are most commonly the consequence of coronary heart disease. They differ fundamentally from supraventricular tachycardia in that they are a common cause of sudden cardiac death (SCD). Their current management has been affected by the following:

(1) The widespread adoption of implantable cardioverter defibrillators (ICDs) for first line prevention of VT and VF.
(2) The recognition of specific syndromes, for example, long QT, which are associated with a high incidence of arrhythmic death attributable to VT and VF.
(3) The recognition that VT occurring in a structurally normal heart is potentially curable by radiofrequency catheter ablation (RFA), and that VT in the setting of structural heart disease is also amenable to effective treatment by RFA [40].



FIG. 15: COMPARISON IF NORMAL HEART AND HEART WITH VENTRICULAR FIBRILLATION

6. Automaticity as a Mechanism of Cardiac Arrhythmias: Abnormal automaticity includes both reduced automaticity, which causes bradycardia, and increased automaticity, which causes tachycardia. Arrhythmias caused by abnormal automaticity can result from diverse mechanisms. Alterations in sinus rate can be accompanied by shifts of the origin of the dominant pacemaker within the sinus node or to subsidiary pacemaker sites elsewhere in the atria. Impulse conduction out of the SA mode can be impaired or blocked as a result of disease or increased vagal activity leading to development of bradycardia. AV junctional rhythms occur when AV junctional pacemakers located either in the AV node or in the His bundle accelerate to exceed the rate of SA node, or when the SA nodal activation rate was too slow to suppress the AV junctional pacemaker. Bradycardia can occur in structurally normal hearts because of genetic mutations that resultin abnormalities of either membrane clock or Ca clock mechanisms of automaticity [41].

6.1 Enhanced Automaticity: Atrial and ventricular myocardial cells do not display spontaneous diastolic depolarization or automaticity under normal conditions, but can develop these characteristics when depolarized, resulting in the development of repetitive impulse initiation, a phenomenon termed depolarization-induced automaticity. The membrane potential at which abnormal automaticity develops ranges between −70 and −30 mV. The rate of abnormal automaticity is substantially higher than that of normal automaticity and is a sensitive function of resting membrane potential (*i.e.,* the more depolarized resting potential the faster the rate). Similar to normal automaticity, abnormal automaticity is enhanced by β-adrenergic agonists and by reduction of external potassium. Depolarization of membrane potential associated with disease states is most commonly a result of

1. An increase in extracellular potassium, which reduces the reversal potential for*I*K1, the outward current that largely determines the resting membrane or maximum diastolic potential;
2. A reduced number of IK_1 channels;
3. A reduced ability of the IK_1 channel to conduct potassium ions; or
4. Electrotonic influence of neighbouring cells in the depolarized zone [42].

7. Genetics of Atrial Fibrillation and Sudden Cardiac Death: The familial event of atrial fibrillation is settled; having an influenced parent copies a person's hazard. Particle channel qualities are emphatically involved in a few families and patients with particle channel sicknesses have an expanded danger of atrial fibrillation. Nonetheless, the clinical heterogeneity of atrial fibrillation has made the examination of fundamental hereditary qualities troublesome. While in a few, atrial fibrillation is nonstop and promptly saw, in others, it is transient, with intense triggers, and can regressor even not be identified by any stretch of the imagination. In that capacity, strict meaning of influenced and unaffected individuals in families or populaces can be tricky. Be that as it may, in spite of such reasonable challenges, defencelessness alleles have been recognized, the first was accounted for to beat chromosomal area. Hereditary arrangement variations at that site have been firmly connected with atrial fibrillation in a few populaces, with the fundamental ensnared competitor quality being PITX2 [43].

8. Causes of Sudden Cardiac Death in Different Age Groups: Cardiac diseases associated with Sudden Cardiac Death (SCD) differ in young individuals versus older individuals. In the young individuals, there is a predominance of channelopathies and cardiomyopathies, myocarditis and substance abuse, while in older populations, chronic degenerative diseases predominate (CAD, valvular heart diseases and HF). Several challenges undermine identification of the cause of SCD in both age groups: older victims, for instance, may suffer from multiple chronic cardiovascular conditions so that it becomes difficult to determine which contributed most to SCD. In younger persons, the cause of SCD may be elusive even after autopsy, because conditions such as inherited channelopathies or drug-induced arrhythmias that are devoid of structural abnormalities are epidemiologically relevant in this age group [44].

9. Cardiac Morbidity and Mortality: In the past 20 years, cardiovascular mortality has decreased in high income countries in response to the adoption of preventive measures to reduce the burden of

CAD and HF. Despite the results, cardiovascular diseases are responsible for approximately 17 million deaths every year in the world, approximately 25% of which are SCD. The risk of SCD is higher in men than in women, and it increases with age due to the higher prevalence of CAD in older age. Accordingly, the SCD rate is estimated to range from 1.40 per 100 000 person-years [95% confidence interval (CI) in women to 6.68 per 100 000 person-years (95% CI6.24, 7.14) in men. SCD in younger individuals has an estimated incidence of 0.46 - 3.7 events per 100 000 person-years, corresponding to a rough estimate of 1100 - 9000 deaths in Europe and 800 - 6200 deaths in the USA every year [45].



FIG. 16: DEATH RATES FOR LEADING CAUSES OF DEATH AMONG PERSONS 65 YEARS OF AGE AND OVER UNITED STATES, 1997-2007

10. Developing New Treatments: An important aim of the development of disease models is to allow responses to therapeutic interventions to be assessed. New models, combined with other features of a systems approach, might well identify molecules the targeting of which could be anti-arrhythmic. These insights might come from family or population genetic approaches, or from laboratory studies of pro-arrhythmic signalling pathways. The potential relevance of individual targets could then be assessed in wild-type or genetically modified organisms derived cardiomyocytes. Encouragingly, mouse models have already been used to provide evidence for drug purposing. For example, flecainide has been shown to directly block ryanodine-receptor mediated calcium release.

11. Future Research: While the recognizable proof of qualities related to essential electrical sickness has advanced at a quick force, understanding into the hereditary qualities of "procured" arrhythmias, for example, in ischemic coronary illness, hypertrophy, heart disappointment or amid the utilization of (QT interim delaying) drugs, is still in its early stages and cases of such investigations are extremely scanty in the writing. The ID of helplessness qualities for procured arrhythmias, together with the ID of hereditary modifiers of essential electrical ailment, really speaks to a foreseen testing following stage in our comprehension of the hereditary qualities of arrhythmias. Here, polymorphisms - that is, basic variations that are available (unessential qualities) all through the genome - are required to impact the vulnerability to arrhythmias. This is probably going to give novel apparatuses to chance stratification and open new open doors for anticipation and treatment of deadly arrhythmias in the regular pathologies [46].

CONCLUSION: Cardiac arrhythmias and ECG abnormalities occur frequently in patients with acute stroke, either with or without coexisting cardiac diseases. The incidence and prevalence of arrhythmias and significantly abnormal ECGs

depend on the types and on set of strokes. The duration and equipment used for cardiac monitoring and criteria used for determination and classification of arrhythmias various steps involved in pathophysiological of arrhythmias to cause the AF and finally sudden death. The master administration of arrhythmias has changed altogether finished the previous decade. This is halfway a result of a noteworthy increment in the confirmation base, mainly in the rate contrasted and mood wrangle for the administration of atrial fibrillation. It is our goal and hope as a next step to promote catheter ablation as a first-line therapy in more patients with AF based on definitive evidence that the procedure reduces mortality and morbidity. In addition, as technology has advanced ablation has found a significant role in the management of all arrhythmias.

ACKNOWLEDGEMENT: Nil

CONFLICTS OF INTEREST: Nil

REFERENCES:

1. Byer E *et al*.: Electro cardiograms with large, upright T-waves and long Q-Tintervals. Am Heart J 1947; 33: 796-806.
2. Durham D: Cardiac Arrhythmias: Diagnosis and Management. The Tachycardias, Department of Critical Care Medicine, Flinders Medical Centre, Adelaide, Critical Care and Resuscitation 2002; 4: 35-53.
3. Bhaumik A *et al*.: Review on cardiac arrhythmia and cardiac ablation: invasive techniques and future perspective; WJPMR, 2016; 2(5): 105-111.
4. Cardiology Self Learning Package, Module 3: Cardiac Arrhythmias: Mechanisms of Arrhythmias, Atrial, Ventricular, Conduction and ST Changes, Developed by Tony Curran (Clinical Nurse Educator) and Gill Sheppard (Clinical Nurse Specialist) Cardiology 2011.
5. Silvia G *et al*.: ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, European Heart Journal 2015; 36: 2793-2867.
6. Jon E: Sprague, Teaching Cardiac Arrhythmias: A Focus on Pathophysiology and Pharmacology, The Raabe College of Pharmacy, Ohio Northern University, Ada OH 45810.
7. Warren M: Fundamentals of Arrhythmias, Bio eng 6460 Electrophysiology and Bioelectricity, Part, Peiss J Electrocardiol 1975.
8. Gary Tse, MA, MBBS, PhD, Mechanisms of cardiac arrhythmias.
9. Charles Antzelevitch, PhD, FHRS and Alexander Burashnikov, PhD, FHRS, Overview of Basic Mechanisms of Cardiac Arrhythmia.
10. Gary Tse, MA, MBBS, PhD, Mechanisms of cardiac arrhythmias, Journal of Arrhythmia 2016; 32: 75-81.
11. Cardiology Self Learning Package, Module 3: Cardiac Arrhythmias: Mechanisms of Arrhythmias, Atrial, Ventricular, Conduction and ST Changes, Developed by Tony Curran (Clinical Nurse Educator) and Gill Sheppard (Clinical Nurse Specialist) Cardiology 2011.
12. Worthley LIG: Cardiac Arrhythmias: Diagnosis and Management. The Tachycardias, Department of Critical Care Medicine, Flinders Medical Centre, Adelaide, Critical Care and Resuscitation 2002; 4: 35-53.
13. Zipes DP: The long QT interval syndrome. A rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation 1991; 84: 1414-9.
14. Plaster NM, Tawil R, Tristani-Firouzi M, *et al*.: Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell. 2001; 105: 511-9.
15. Wang Q, Shen J, Splawski I, *et al*.: SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80: 805-11.
16. Mohler PJ, Schott JJ, Gramolini AO, *et al*.: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003; 421: 634-9.
17. Curran ME, Splawski I, Timothy KW, *et al*.: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995; 80: 795-803.
18. Wang Q, Curran ME, Splawski I, *et al*.: Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996; 12: 17-23.
19. Splawski I, Tristani-Firouzi M, Lehmann MH, *et al*.: Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997; 17: 338-40.
20. Ye B, Tester DJ, Vatta M, *et al*.: Molecular and functional characterization of novel cav3-encoded cav-eolin-3 mutations in congenital long QT syndrome [abstract]. Heart Rhythm 2006; 3: S1.
21. Domingo AM, Kaku T, Tester DJ, *et al*.: Sodium channel β4 subunit mutation causes congenital long QT syndrome. Heart Rhythm 2006; 3: S34.
22. Splawski I, Timothy KW, Sharpe LM, *et al*.: Cav1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell. 2004; 119: 19-31.
23. Yang Y, Yang Y, Liang B, *et al*.: Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet. 2010; 86: 872-80. .
24. Noble D: Biophysics and systems biology. Philos Transact A Math Phys Eng Sci. 2010; 368: 1125- 39.
25. Weiss JN, Nivala M, Garfinkel A, Qu Z: Alternans and arrhythmias: from cell to heart. Circ Res. 2011; 108: 98-112.
26. Papadatos GA, Wallerstein PM, Head CE, *et al*.: Slowed conduction and ventricular tachycardia after targeted disruption of the cardiac sodium channel gene Scn5a. Proc Natl Acad Sci USA. 2002; 99: 6210-15.
27. Watanabe H, Yang T, Stroud DM, *et al*.: Striking *in vivo* phenotype of a disease-associated human SCN5A mutation producing minimal changes in vitro. Circulation 2011; 124: 1001-11.
28. Jeyaraj D, Haldar SM, Wan X, *et al*.: Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature. 2012; 483: 96-99
29. Magnani JW, Rienstra M, Lin H, *et al*.: Atrial fibrillation: current knowledge and future directions in epidemiology and genomics. Circulation. 2011; 124: 1982-93.
30. Rienstra M, Lubitz SA, Mahida S, *et al*.: Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities. Circulation. 2012; 125: 2933-43.

31. Morady F: Catheter ablation of supraventricular arrhythmias: state of the art. Pacing Clin Electrophysiol 2004; 27: 125–42.
32. Shah DC, Haissaguerre M, Takahashi A, *et al*.: Differential pacing for distinguishing block from persistent conduction through an ablation line. Circulation 2000; 102: 1517-22.
33. Shah DC, Takahashi A, Hocini M, *et al*.: Local electrogram-based criteria of cavotricuspid isthmus block. J Cardiovasc Electrophysiol 1999; 10: 662-9.
34. Cauchemez B, Haissaguerre M, Fischer B, *et al*.: Electrophysiological effects of catheter ablation of inferior cava- tricuspid annulus isthmus in common atrial flutter. Circulation 1996; 93: 284–94.
35. Natale A, Newby KH, Pisano E, *et al*.: Prospective randomized comparison of antiarrhythmic therapy versus radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 2000; 35: 1898-904.
36. Nabar A, Rodriguez LM, Timmermans C, *et al*.: Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: Observations in four patients having type I atrial flutter with or without associated atrial fibrillation. Circulation 1999; 99: 1441–5.
37. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham study. Arch Intern Med 1987; 145: 1561-4.
38. Wolf P, Mitchell J, Baker C, *et al*.: Impact of atrial fibrillation on mortality, stroke and medical costs. Arch Intern Med 1998; 158: 229-34.
39. Reimold SC, Cantillon CO, Friedman PL, *et al*.: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-63.
40. Coplen SE, Antman EM, Berline JA, *et al*.: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
41. Kontula K, Laitinen PJ, Lehtonen A, *et al*.: Catecholaminergic polymorphic ventricular tachycardia: recent mechanistic insights. Cardiovasc Res 2005; 67: 379-87.
42. Wilde AA and Roden DM: Predicting the long-QT genotype from clinical data: from sense to science. Circulation 2000; 102: 2796-8.
43. Schwartz PJ, Priori SG, Spazzolini C, *et al*.: Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103: 89-95.
44. Groenewegen WA, Firouzi M, Bezzina CR, *et al*.: A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ Res 2003; 92: 14-22.
45. Clancy CE and Kass RS: Inherited and acquired vulnerability to ventricular arrhythmias: cardiac Na+ and K+ channels. Physiol Rev 2005; 85: 33-47.
46. Mohler PJ, Schott JJ, Gramolini AO, *et al*.: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003; 421: 634-9.

How to cite this article:
Paul AD and Manogna K: Cardiac arrythmiasis and its detailed pathophysiology - A review. Int J Pharm Sci & Res 2018; 9(4): 1363-76. doi: 10.13040/IJPSR.0975-8232.9(4).1363-76.